Treating Patients with Complex Metabolic Conditions

Allena Pharmaceuticals, Inc. is a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral protein therapeutics to patients with serious renal, urologic, and orphan diseases. Allena is currently conducting a Phase 2 program for its lead product candidate, ALLN-177, in patients with hyperoxaluria. The company’s technological approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by degrading toxic metabolites, without being absorbed into the bloodstream.

Year Invested: 2011
Location: Newton, Mass.

Recent News

March 3, 2017
Allena Pharmaceuticals to Present at The Cowen And Company 37th Annual Health Care Conference

January 5, 2017
Allena Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

October 4, 2016
Allena Pharmaceuticals and Health Advances Present Analysis of Recurrent Kidney Stone Disease at the Academy of Managed Care Pharmacy Nexus Conference

Read More News

Associated Team Members

Robert Tepper, M.D.